Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL002 in Early Alzheimer's Disease (LTE)
NCT05744401Phase 2Terminated
- Sponsor
- Alector
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, double-blind trial of AL002 in Alzheimer's disease (AD) (3 arms), sponsored by Alector. Primary endpoints: Treatment-emergent Adverse Events at 49 weeks, Serious Adverse Events and Adverse Events of Special Interest at 49 weeks and 4 more. Started Jan 2023; status: terminated.
02
Drugs
AL002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05744401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05744401.